Brief: Redhill Biopharma Announces New Agreement With Daiichi Sankyo For Movantik

Redhill Biopharma

03/08/2020 12:19

Aug 3 (Reuters) - Redhill Biopharma Ltd  REDIF.PK :
    * REDHILL BIOPHARMA LTD - ANNOUNCES NEW AGREEMENT WITH
DAIICHI
SANKYO FOR MOVANTIK
    * REDHILL BIOPHARMA LTD - REDHILL WILL BEAR ALL
RESPONSIBILITIES
AND COSTS FOR COMMERCIALIZING MOVANTIK IN U.S.
    * REDHILL BIOPHARMA - WILL PAY DAIICHI SANKYO A MID-TEEN
ROYALTY
RATE ON NET SALES OF MOVANTIK IN U.S., 3 LUMP SUM PAYMENTS EACH
YEAR STARTING IN 2021
    * REDHILL BIOPHARMA LTD - COMPANIES ALSO ENTERED A
SUBSCRIPTION
AGREEMENT UNDER WHICH DAIICHI SANKYO RECEIVED 283,387 IN ADS OF
REDHILL

Source text for Eikon:  ID:nGNX7glSWr 
Further company coverage:  REDIF.PK 

 ((Reuters.Briefs@thomsonreuters.com;))